Editorial: Targeting Membrane Proteins: Structure-Function-Dynamics Relationships

Claire Colas1*, Ivet Bahar2*, Lei Shi3* and Josep Font Sadurni4*

1Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria, 2Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States, 3Computational Chemistry and Molecular Biophysics Section, National Institute on Drug Abuse – Intramural Research Program, National Institutes of Health, Baltimore, MD, United States, 4Transporter Biology Group, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia

Keywords: membrane proteins, drug targets, structure, function, dynamics

Editorial on the Research Topic

Targeting Membrane Proteins: Structure-Function-Dynamics Relationships

Recent years have seen significant advances in the structure-based characterization of the mechanisms of function of membrane proteins, in particular transporters, and in the development of allosteric modulator and pharmacological agents that regulate their function. This issue provides examples from recent progress in the field, along with additional studies on ion channeling and secretion of proteins at the ER.

Solute carrier (SLC) transporters constitute a major membrane protein target class. The SLC6 family is one of the most studied SLC family, notably the monoamine transporter subgroup, containing neurotransmitter sodium symporters (NSS) such as norepinephrine, dopamine and serotonin transporters. The pharmacology of these transporters has been studied for many years due to their high therapeutic impact. Recently, particular emphasis has been put on structure-based methods, with the aim of deciphering the molecular determinants involved in ligand binding specificities. Three studies in this collection focus on SLC6 members. Frangos et al. analyze three allosteric sites described in literature for members of the SLC6 family, and explore how these sites can be targeted for the modulation of the glycine transporter GlyT2, an emerging target in the SLC6 family. Kickinger et al. on the other hand, describe the structural determinants for the activity of a novel class of inhibitors of the Betaine/GABA transporter BGT1 (a member of the GABA transporter subgroup of the SLC6 family). Romanazzi et al. draw attention to the role of bile acids, molecules derived from cholesterol, and in particular that of the obeticholic acid in regulating channel-like activity of dopamine transporter. Together, these studies provide new building blocks to further functionally characterize and modulate the activities of the members of this important family of neurotransmitter transporters, which could open new avenues for pharmacological treatments of SLC6-related brain disorders.

The current collection also has two interesting studies on antiporters. Antiporters are secondary transporters that transport two (or more) substrates, ions or small molecules, in opposite directions across the membrane. The first study is on a human zinc transporter 1 (hZnT1) that shows Zn2+/H+ antiporter activity in the presence of detergent and cholesteryl hemisuccinate. hZnT1 export Zn2+ from the cytoplasm to protect cells from Zn2+ toxicity. Cotrim et al. were able to express the soluble
C-terminal domain of hZnT1 (hZnT1-CTD) in a bacterial expression system, and found an increase in the melting temperature of the hZnT1-CTD at acidic pH, while the small-angle X-ray scattering analysis indicated that hZnT1-CTD forms a dimer in solution with a V-shaped core. These findings provide a basis for the structure-function studies of hZnT1 and its close homologs. The second is on the archaeal Na+/Ca2+ exchanger, as a model system to study the mechanism of function of the superfamily of Ca2+/Cation antiporters. Khananshvili presents an extensive review of the current understanding of the mechanism of function of this exchanger.

Inwardly rectifying potassium (Kir) channels are regulated by ligands such as Na+ and H+, adenosine nucleotides, and lipid phosphatidyl-inositol 4,5-bisphosphate (PIP2). The latter is an essential activator for eukaryotic members of the Kir family, but its specific binding and action on Kir6.2 has eluded characterization despite the resolution of several X-ray and cryo-EM structures for PIP2-bound Kir channels. Bründl et al. simulated PIP2-induced gating events allowing for the channeling of potassium across the Kir6.2 pore of ATP-sensitive potassium channels, using the structural data available for PIP2-bound homologs Kir2 and Kir3 together with functional data. The study provides information on the molecular structure and dynamics of Kir pore in the presence of PIP2, as well as the order of events that enable the stepwise regulation of Kir6.2 activity by PIP2. Furthermore, the authors examined the effect of the point mutation L164P associated with Permanent Neonatal Diabetes, to show how this mutation influences pore geometry and disrupts stability.

The carboxy terminus of an endoplasmic reticulum (ER) resident proteins typically have an ER retention/retrieval sequence (ERS), which usually contains the canonical Lys-Asp-Glu-Leu (KDEL) motif. KDEL receptors (KDELRs) in the Golgi recognize the ERS and return the protein to the ER lumen. By combining machine learning-based modeling and experimental validation, Trychta et al. identified the ERS divergent from the canonical “KDEL” motif. Using molecular modeling and simulations, they showed that two representative non-canonical ERS can stably bind to the KDELRs, which employs interactions beyond the final four residues of the ERS. Their work established an integrated platform to predict whether a carboxy-terminal sequence acts as a putative ERS. The ability to predict which proteins may be secreted may shed light to the complex relationship between disruptions in ER homeostasis and diverse pathologies.

AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

FUNDING
This work is partially supported by National Institutes of Health, National Institute on Drug Abuse – Intramural Research Program (ZIA DA000606, LS).

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Colas, Bahar, Shi and Font Sadurni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.